Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 3
1980 7
1981 13
1982 4
1983 8
1984 5
1985 11
1986 10
1987 13
1988 11
1989 13
1990 10
1991 15
1992 16
1993 22
1994 44
1995 34
1996 33
1997 33
1998 43
1999 53
2000 53
2001 56
2002 86
2003 122
2004 133
2005 157
2006 178
2007 184
2008 287
2009 275
2010 361
2011 467
2012 544
2013 655
2014 860
2015 890
2016 923
2017 1135
2018 1208
2019 1377
2020 1602
2021 1813
2022 2043
2023 1954
2024 730

Text availability

Article attribute

Article type

Publication date

Search Results

16,526 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. Among authors: xu b. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. Among authors: xu b. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Ribociclib plus Endocrine Therapy in Early Breast Cancer.
Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Ruiz-Borrego M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Afenjar K, Fresco R, Severin I, Ji Y, Ghaznawi F, Li Z, Zarate JP, Chakravartty A, Taran T, Hortobagyi G. Slamon D, et al. Among authors: xu b. N Engl J Med. 2024 Mar 21;390(12):1080-1091. doi: 10.1056/NEJMoa2305488. N Engl J Med. 2024. PMID: 38507751 Clinical Trial.
Acupuncture for cancer pain: an evidence-based clinical practice guideline.
Ge L, Wang Q, He Y, Wu D, Zhou Q, Xu N, Yang K, Chen Y, Zhang AL, Hua H, Huang J, Hui KK, Liang F, Wang L, Xu B, Yang Y, Zhang W, Zhao B, Zhu B, Guo X, Xue CC, Zhang H; International Trustworthy traditional Chinese Medicine Recommendations (TCM Recs) Working Group. Ge L, et al. Among authors: xu b. Chin Med. 2022 Jan 5;17(1):8. doi: 10.1186/s13020-021-00558-4. Chin Med. 2022. PMID: 34983587 Free PMC article. Review.
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L, Denkert C, Fallenberg EM, Francis PA, Gamal-Eldin H, Gelmon K, Geyer CE, Gnant M, Guarneri V, Gupta S, Kim SB, Krug D, Martin M, Meattini I, Morrow M, Janni W, Paluch-Shimon S, Partridge A, Poortmans P, Pusztai L, Regan MM, Sparano J, Spanic T, Swain S, Tjulandin S, Toi M, Trapani D, Tutt A, Xu B, Curigliano G, Harbeck N; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Loibl S, et al. Among authors: xu b. Ann Oncol. 2024 Feb;35(2):159-182. doi: 10.1016/j.annonc.2023.11.016. Epub 2023 Dec 13. Ann Oncol. 2024. PMID: 38101773 No abstract available.
Ion channel TRPV2 is critical in enhancing B cell activation and function.
Li C, Zhao M, Liu X, Li Y, Xu B, Zhou L, Sun X, Sun W, Kang N, Ji Z, Li T, An H, Wang F, Wu C, Ye JY, Zhang JR, Wang Q, Zhao X, Li Z, Liu W. Li C, et al. Among authors: xu b. J Exp Med. 2024 Mar 4;221(3):e20221042. doi: 10.1084/jem.20221042. Epub 2024 Feb 14. J Exp Med. 2024. PMID: 38353705
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; IMpassion131 investigators. Miles D, et al. Among authors: xu b. Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1. Ann Oncol. 2021. PMID: 34219000 Free article. Clinical Trial.
A Reporting Tool for Practice Guidelines in Health Care: The RIGHT Statement.
Chen Y, Yang K, Marušic A, Qaseem A, Meerpohl JJ, Flottorp S, Akl EA, Schünemann HJ, Chan ES, Falck-Ytter Y, Ahmed F, Barber S, Chen C, Zhang M, Xu B, Tian J, Song F, Shang H, Tang K, Wang Q, Norris SL; RIGHT (Reporting Items for Practice Guidelines in Healthcare) Working Group. Chen Y, et al. Among authors: xu b. Ann Intern Med. 2017 Jan 17;166(2):128-132. doi: 10.7326/M16-1565. Epub 2016 Nov 22. Ann Intern Med. 2017. PMID: 27893062
16,526 results
You have reached the last available page of results. Please see the User Guide for more information.